文献速递MDS 与骨髓增殖性肿瘤

铁是JAK2突变骨髓增殖性肿瘤表型的修饰因素

Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
PubMed 文献 · Blood · 2023-01-01

研究在小鼠模型中探讨铁可利用性对JAK2-V617F及外显子12突变(E12)骨髓增殖性肿瘤表型的影响。PV样表型小鼠基线存在铁缺乏,低铁饮食增加血小板而减少红细胞;注射铁剂使PV样小鼠血小板下降、血红蛋白和血细胞比容进一步升高;铁调素类似物vamifeport和PR73可正常化PV模型的血细胞比容和血红蛋白。

要点

  • PV样JAK2突变小鼠基线存在铁缺乏,ET样突变小鼠铁储备正常。
  • 低铁饮食使JAK2突变及野生型小鼠血小板生成增加、红细胞减少。
  • 铁剂注射使PV样小鼠血小板下降、血红蛋白和血细胞比容进一步升高。

核心结论

  • 铁可利用性可修饰JAK2突变骨髓增殖性肿瘤的表型,铁转运蛋白抑制剂和minihepcidin可能用于PV患者的治疗。

研究设计与样本

  • 研究在表达JAK2-V617F及JAK2外显子12 N542-E543del突变(E12)的小鼠模型中检查铁可利用性对MPN表型的影响,并设野生型(WT)对照。

主要发现

  • 基线对照饮食下,所有PV样表型的JAK2突变小鼠模型均显示铁缺乏,E12小鼠较JAK2-V617F突变小鼠保留更多铁用于增强的红细胞生成。
  • ET样表型的JAK2-V617F突变小鼠铁储备正常,与WT小鼠相当。
  • 低铁饮食下,JAK2突变小鼠和WT对照均以红细胞为代价增加血小板生成。
  • PV表型小鼠经肠外铁剂注射后血小板计数下降、血红蛋白和血细胞比容进一步升高,而WT对照无变化。
  • 铁可利用性改变主要影响前巨核细胞-红细胞祖细胞,该群体构成JAK2突变小鼠红系生成的铁反应阶段。

临床怎么用

  • 作者认为铁转运蛋白抑制剂和minihepcidin可用于PV患者的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

JAK 2-V617F mutation causes myeloproliferative neoplasms (MPNs) that can manifest as polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis. At diagnosis, patients with PV already exhibited iron deficiency, whereas patients with ET had normal iron stores. We examined the influence of iron availability on MPN phenotype in mice expressing JAK2-V617F and in mice expressing JAK2 with an N542-E543del mutation in exon 12 (E12). At baseline, on a control diet, all JAK2-mutant mouse models with a PV-like phenotype displayed iron deficiency, although E12 mice maintained more iron for augmented erythropoiesis than JAK2-V617F mutant mice. In contrast, JAK2-V617F mutant mice with an ET-like phenotype had normal iron stores comparable with that of wild-type (WT) mice. On a low-iron diet, JAK2-mutant mice and WT controls increased platelet production at the expense of erythrocytes. Mice with a PV phenotype responded to parenteral iron injections by decreasing platelet counts and further increasing hemoglobin and hematocrit, whereas no changes were observed in WT controls. Alterations of iron availability primarily affected the premegakaryocyte-erythrocyte progenitors, which constitute the iron-responsive stage of hematopoiesis in JAK2-mutant mice. The orally administered ferroportin inhibitor vamifeport and the minihepcidin PR73 normalized hematocrit and hemoglobin levels in JAK2-V617F and E12 mutant mouse models of PV, suggesting that ferroportin inhibitors and minihepcidins could be used in the treatment for patients with PV.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stetka J, Usart M, Kubovcakova L, et al. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023. PMID: 36758212. doi:10.1182/blood.2022017976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。